Related Experiment Video
Updated: May 25, 2025

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel
Published on: May 14, 2018
Small Molecules Identified by an In Silico Docking Screen Targeting Anaphase-Promoting Complex/Cyclosome Subunit 1
Scott C Schuyler1,2, Rythm Gupta1,3, Tran Thi Bao Nguyen1
1Department of Biomedical Sciences, College of Medicine, Chang Gung University, Kwei-Shan, Taoyuan 333, Taiwan.
Abstract:
Delaying mitotic cell cycle progression has been proposed as a strategy to potentiate the effects of anti-mitotic anti-cancer drugs that induce multipolar mitotic spindles. Toward this end, we have performed an in silico docking screen targeting anaphase-promoting complex/cyclosome subunit 1 (APC1) at a conserved 10-amino acid surface site that was modeled to interact via a single hydrogen bond with the essential mitotic anaphase-promoting complex/cyclosome (APC/C) co-factor cell division cycle 20 (CDC20). Five molecules were identified after screening 15,000 small molecules. As a secondary in cellulo bioactivity screening, MDA-MB-231 genomically unstable aneuploid breast cancer cells were exposed to each compound in the absence and presence of 10 nM paclitaxel or 1 nM eribulin, the likely clinically relevant doses of these drugs in these cells. Two of the five compounds, which share a common 2-(trifluoromethyl)quinazolin-4-amine chemical structure, induced elevated levels of cell death in combination with paclitaxel, as observed by fluorescence-activated cell sorting (FACS). These two compounds will now serve as a starting point for further optimization and target validation experiments and for additional in silico screens in search of other chemically related small molecules that display more potent but specific anti-cancer cell effects.
Insights
Researchers screened 15,000 molecules to find compounds that enhance anti-cancer drug efficacy. Two compounds targeting the anaphase-promoting complex/cyclosome (APC/C) showed promise in increasing cancer cell death when combined with paclitaxel.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Anti-mitotic drugs are crucial cancer therapies.
- Enhancing their efficacy by targeting cell cycle progression is a key strategy.
- The anaphase-promoting complex/cyclosome (APC/C) is a critical regulator of mitosis.
Purpose of the Study:
- To identify small molecules that inhibit the APC/C co-factor CDC20.
- To evaluate the synergistic effects of identified compounds with anti-mitotic drugs in cancer cells.
Main Methods:
- In silico docking screen of 15,000 small molecules against APC1.
- In cellulo bioactivity screening using MDA-MB-231 breast cancer cells.
- Combination treatment with paclitaxel or eribulin, followed by FACS analysis.
Main Results:
- Five small molecules were identified via in silico screening.
- Two compounds with a 2-(trifluoromethyl)quinazolin-4-amine structure enhanced paclitaxel-induced cell death.
- These compounds showed synergistic effects in combination therapy.
Conclusions:
- Identified compounds are promising starting points for developing novel anti-cancer therapeutics.
- Further optimization and target validation are warranted.
- The strategy of targeting APC/C in combination with anti-mitotic drugs shows potential for cancer treatment.
More Related Videos
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Related Concept Videos
Drugs that Stabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs that Destabilize Microtubules
Anaphase Promoting Complex
Inhibition of Cdk Activity
The Intrinsic Apoptotic Pathway